Concepedia

Zhongyuan Zhu

ZZ

Statistics

Publications

3

Citations

46

H-Index

3

Active since

2023

Affiliations

Duality (United States)(Current)

Zhongyuan Zhu is an author at Duality (United States) specializing in targeted cancer therapy, solid tumor applications, and targeted therapy.

Publications per year

2023–2024

3

Publications

3

DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models

Shengchao Lin, Yu Zhang, Jun Yao et al. · Journal of Translational Medicine · 2024 · 21 citations · Full text

, , +17

DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors

Xi Li, Jun Yao, Qu Chen et al. · Journal of Translational Medicine · 2024 · 14 citations · Full text

, , +16

An immunomodulatory antibody–drug conjugate targeting BDCA2 strongly suppresses plasmacytoid dendritic cell function and glucocorticoid responsive genes

Xi Li, Yu Zhang, Bing Li et al. · Lara D. Veeken · 2023 · 11 citations · Full text

, , +17

1–3 of 3